Use of the continuous glucose monitoring system in the management of hypoglicemia in insulin autoimmune syndrome

1. Serban V, Sima A, Popa S. Endogenous hypoglycemia. Metabolic diseases. Brumar, 2010: 189-199. Search in Google Scholar

2. Censi S, Mian C, Betterle C. Insulin autoimmune syndrome: from diagnosis to clinical management. Ann Transl Med. 2018;6(17):335.10.21037/atm.2018.07.32 Search in Google Scholar

3. Saxon DR, McDermott MT, Michels AW. Novel Management of Insulin Autoimmune Syndrome with Rituximab and Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2016;101(5):1931-1934.10.1210/jc.2016-1097 Search in Google Scholar

4. Uchigata Y, Hirata Y. Insulin autoimmune syndrome (Hirata Disease). In Immunoendocrinology: Scientific and Clinical Aspects. Totowa, NJ: Humana Press, 2011:343-67.10.1007/978-1-60327-478-4_21 Search in Google Scholar

5. Uchigata Y, Hirata Y, Omori Y, Iwamoto Y, Tokunaga K. Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol. 2000;61(2):154-157.10.1016/S0198-8859(99)00144-5 Search in Google Scholar

6. Advani A. Positioning time in range in diabetes management. Diabetologia. 2020;63(2):242-252.10.1007/s00125-019-05027-031701199 Search in Google Scholar

7. Ismail AA. The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis. Clin Chem Lab Med. 2016;54(11):1715-1724.10.1515/cclm-2015-125527071154 Search in Google Scholar

8. Wong SL, Priestman A, Holmes DT. Recurrent hypoglycemia from insulin autoimmune syndrome. J Gen Intern Med. 2014;29(1):250-254.10.1007/s11606-013-2588-9388995923979685 Search in Google Scholar

9. Cappellani D, Macchia E, Falorni A, Marchetti P. Insulin Autoimmune Syndrome (Hirata Disease): A Comprehensive Review Fifty Years After Its First Description. Diabetes Metab Syndr Obes. 2020;13:963-978.10.2147/DMSO.S219438713666532308449 Search in Google Scholar

10. Eguchi Y, Uchigata Y, Yao K, Yokoyama H, Hirata Y, Omori Y. Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome (Hirata’s disease). Autoimmunity.1994;19(4):279-284.10.3109/089169394090713547578855 Search in Google Scholar

11. Ismail AA. The double whammy of endogenous insulin antibodies in non-diabetic subjects. Clin Chem Lab Med. 2008;46(2):153-6.10.1515/CCLM.2008.03118324904 Search in Google Scholar

12. Uchigata Y, Hirata Y, Iwamoto Y. Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract. 2009;83(1):e19-e20.10.1016/j.diabres.2008.10.01519070385 Search in Google Scholar

13. Censi S, Albergoni M, Gallo N, Plebani M, Boscaro M, Betterle C. Insulin autoimmune syndrome (Hirata’s disease) in an Italian patient: a case report and review of the literature. Clinical Chem Lab Med.2018;56(6):889-895.10.1515/cclm-2017-039228917079 Search in Google Scholar

14. Philippon M, Sejil S, Mugnier M, et al. Use of the continuous glucose monitoring system to treat insulin autoimmune syndrome: quantification of glucose excursions and evaluation of treatment efficacy. Diabet Med. 2014;31(7):e20-e24.10.1111/dme.1241825077287 Search in Google Scholar